Design, Synthesis, Spectroscopic Characterisation and In Vitro Cytostatic Evaluation of Novel Bis(coumarin-1,2,3-triazolyl)benzenes and Hybrid Coumarin-1,2,3-triazolyl-aryl Derivatives

Kristina Pršir 1, Ema Horak 1,2, Marijeta Kralj 3, Lidija Uzelac 3, Sandra Liekens 4, Ivana Murković Steinberg 1 and Svjetlana Kristafor 1,*

1. Introduction

Coumarin (2H-chromen-2-one) has become a privileged heterocyclic moiety in biomedical chemistry and novel drug discovery. The chemistry of coumarin has been profoundly examined as a result of its wide distribution in nature, and the extensive biological activity of its derivatives, including anticancer [1,2], antioxidant [3], antiviral [4], antibacterial [5]. Due to its lipophilic, aromatic and planar structure, the coumarin ring can easily bind different biological targets by π-π, hydrogen or dipole–dipole interactions and therefore is incorporated in the structure of various important bioactive compounds [6].

In addition, the therapeutic potential of coumarins strongly depends on their basic structure [7] as seen in simple, bis- and fused polycyclic coumarins [8–12]. Furthermore, the nature and position of substituents on the benzopyrone core can affect the pharmacological properties and biological activities of the resulting molecule. Design and synthesis of coumarin-based hybrid molecules by introducing one or more heterocyclic moieties in the coumarin core is a promising approach in the development of novel therapeutic agents with improved and diverse activity [13].
In the context of easy structural modification, the concept of click chemistry has received great attention. The Cu(I)-catalysed Huisgen 1,3-dipolar cycloaddition is considered to be the typical click reaction in which 1,4-disubstituted 1,2,3-triazole is formed [14–16]. Over the past decade, the 1,2,3-triazole ring has emerged as one of the most important building blocks in the synthesis of molecular hybrids, and a vast number of molecules have been developed on the basis of this structure [17]. Besides the synthetic simplicity and modular nature of the reaction, aromatic 1,2,3-triazoles obtained in this way have an important effect on the pharmacological profile of the resulting molecule. Triazole rings mostly act as linkers between various heterocyclic motifs in molecular hybrids, but can also directly participate in the binding of the target analyte. Because of the large dipole moment, triazoles can act as hydrogen bond donors, mimicking amide functional group. More importantly, they are resistant to metabolic degradation and hydrolysis, and are stable under acidic, basic and redox conditions in living biological systems.

In recent years, derivatives conjugated with 1,2,3-triazole at the C-3, C-4 and C-7 positions of the coumarin ring have been evaluated as promising antitumour (I) [18,19], anti-inflammatory (II) [20], neuroprotective (III) [21] and antitubercular agents (IV–V) [8,22], and representatives are shown in Figure 1.

**Figure 1.** 1,2,3-Triazolyl-coumarin-hybrids as bioactive molecules.

Another essential class of nitrogen containing heterocycles in novel drug development is benzofused azoles. Benzimidazole and benzothiazole represent important pharmacophores in medicinal chemistry, primarily because of their structural similarity with naturally occurring molecules. Among the various benzazole-based compounds, 2-thiobenzazoles have attracted considerable attention in medicinal research and their deriva-
we have employed a molecular hybridisation strategy in order to design new hybrids that potentially suitable for application in fluorescence bioimaging. Coumarins are well-known fluorophores in labelling of biomolecules [27] because of the relatively large Stokes shift and high quantum yields, while in combination with 1,2,3-triazoles, new opportunities are opening up to investigate their potential as fluorescent probes for detecting biologically and environmentally important metal cations [23,25,24]. Therefore, we have employed a molecular hybridisation strategy in order to design new hybrids or conjugates with improved and diverse pharmacological properties [13,17]. Therefore, the antiproliferative activity and basic photophysical properties of these newly prepared hybrids has been examined.

Figure 2. 2-Thiobenzazole scaffold in bioactive molecules.

Despite the large number of known bioactive coumarin-based molecules, there is a need for novel therapeutic agents with improved activity, especially those substituted at C-7 position of the coumarin ring. Taking into account the expressed activity of these three classes of heterocycles, their combination in one target molecule may lead to enhanced bioactivity when compared to individual entities. This type of molecular hybridisation is considered an effective and powerful tool in drug discovery for development of novel hybrids or conjugates with improved and diverse pharmacological properties [13,17]. Therefore, we report the synthesis of hybrids containing coumarin and 1,2,3-triazole moieties in one scaffold, via a Cu(I)-catalysed 1,3-dipolar cycloaddition reaction of 7-azidocoumarin and terminal alkynes. The compounds consist of 7-(1,2,3-triazolyl)coumarin as a central backbone and aryl-substituted subunit linked to the 4-position of the triazole ring. Moreover, planar bis-(coumarin-1,2,3-triazolyl)benzenes were designed by connecting two 7-(1,2,3-triazolyl)coumarin nuclei to enhance the activity allowing additional interactions. Further modification of the triazolyl-coumarin core was carried out by introducing benzofused heterocycles through a thiomethylene linker. In addition to the compounds being potentially biologically active, fluorescence was observed with some of them, making them potentially suitable for application in fluorescence bioimaging. Coumarins are well-known fluorophores in labelling of biomolecules [27] because of the relatively large Stokes shift and high quantum yields, while in combination with 1,2,3-triazoles, new opportunities are opening up to investigate their potential as fluorescent probes for detecting biologically and environmentally important metal cations [28,29], anions [30] and biomolecules [31]. Therefore, the antiproliferative activity and basic photophysical properties of these newly prepared hybrids has been examined.

2. Results and Discussion

2.1. Synthesis

The synthesis of 1,2,3-triazolyl-coumarin hybrids 2a–i is outlined in Scheme 1. Azido coumarin 1, as a key precursor, was synthesised by two methods using commercially available 7-amino-4-methylcoumarin as starting material. Transformation of amino group

---

**Figure 2.** 2-Thiobenzazole scaffold in bioactive molecules.
to azido substituent in 1 comprised of diazotization and nucleophilic substitution of traditional diazonium salt with azidotrimethylsilane, TMSN$_3$ (Method A) [32] or diazotization and tosylation followed by nucleophilic substitution of corresponding coumarinyldiazonium tosylate (ArN$_2^+$TsO$^-$) with NaN$_3$ as azide source (Method B) [33]. In the simple and practical Method A, tert-butyl nitrite (t-BuONO) was used as diazotizing agent for 7-amino-4-methylcoumarin followed by reaction of arenediazonium salt thus obtained with TMSN$_3$. Alternatively, Method B involved a one-pot procedure to azidocoumarin 1 via the non-usual diazonium tosylate as an intermediate. Conversion of 7-amino-4-methylcoumarin to the corresponding azide 1 started by diazotization with NaN$_2$O in water in the presence of p-toluenesulfonic acid, PTSA, followed by azide substitution with NaN$_3$. Neither method required purification and afforded the pure azidocoumarin 1 without isolation of diazonium intermediates, but Method B provided 1 in better yield (68% and 40%, respectively). Azidocoumarin 1 was then subjected to copper-catalysed Huisgen 1,3-dipolar cycloaddition with various commercially available or synthesised aromatic terminal alkynes and target 1,4-disubstituted 1,2,3-triazolyl-coumarin conjugates 2a–i were prepared.

![Scheme 1](image)

**Scheme 1.** Synthesis of triazolyl-coumarin conjugates 2. Reagents and conditions: (a) Method A: t-BuONO, TMSN$_3$, CH$_3$CN, rt., 2 h; Method B: p-TsOH, NaNO$_2$, NaN$_3$, rt., overnight; (b) alkyne, CuSO$_4$, Na ascorbate, TBTA, t-BuOH/H$_2$O/CH$_2$Cl$_2$, 24–72 h, 25–60 °C.

The Cu(I) catalyst was generated in situ from Cu(II) salt using sodium ascorbate as reducing agent. To enhance the catalytic effect of Cu(I) in theazole-alkyne click reaction, polytriazolylamine ligand, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, TBTA [34] was also used and compounds 2a–i were obtained in low to moderate yields (11% to 59%). Propargylated benzazole derivatives 3a and 3b were prepared via nucleophilic addition of propargyl bromide with 2-mercaptobenzthiazole or 2-mercaptobenzimidazole in the presence of K$_2$CO$_3$ as a base (Scheme 2). Finally, the Cu-catalysed Huisgen cycloaddition reaction of azidocoumarin 1 and propargyl benzazoles 3a and 3b yielded the desired coumarin-triazole-benzazole hybrids 4a and 4b, respectively.
Scheme 2. Synthesis of triazolyl-coumarin conjugates 4. Reagents and conditions: (a) propargyl bromide, K$_2$CO$_3$, THF, 60 °C, 4 h; (b) CuSO$_4$, Na-ascorbate, t-BuOH/H$_2$O (1:1), rt., 24 h.

2.2. Antitumoral Activity In Vitro

Compounds 2a–i, 4a and 4b were evaluated for their in vitro cytostatic activities against a panel of human malignant tumour cell lines, as follows: colon carcinoma (HCT116), breast adenocarcinoma (MCF-7), lung carcinoma (H 460), human T-lymphocyte cells (CEM), human cervix carcinoma cells (HeLa). In addition, we included one non-tumour cell line, human dermal microvascular endothelial cells (HMEC-1), to evaluate the selectivity of the newly prepared compounds. The biological data are presented in Table 1 and Figure 3. Amongst all coumarin-1,2,3-triazole-aryl hybrids 2a–g, compound 2b bearing an aminophenyl moiety showed the most pronounced cell cytotoxicity and selectivity against the MCF-7 cell line with an IC$_{50}$ = 0.6 μM. Besides, compound 2b also showed significant cytotoxic activity against HCT116 cell line with IC$_{50}$ = 3 μM. Interestingly, its N,N-dimethylated analogue 2c indicated loss of activity and retained only moderate inhibitory effect against MCF-7 with IC$_{50}$ = 21 μM. Furthermore, compound 2a with an unsubstituted phenyl moiety at 1,2,3-triazole ring did not show any specific cytostatic activity. Moreover, introduction of methyl (2d), methoxy (2f) or formyl substituents (2g) at the phenyl moiety of the molecular structure did not have any favourable effect on the cytostatic activity of the conjugates, and only moderate activity against HCT116 cell line was observed (IC$_{50}$ = 36, 22 and 77 μM, respectively). In addition, the bromo substituent on the phenyl ring in 2e had mild influence on cytotoxicity against tested cell lines.

Table 1. IC$_{50}$ values (μM) of tested compounds against HCT116, MCF-7, H 460, CEM, HeLa, HMEC-1 cells.

| Compound | HCT116 | MCF-7 | H 460 | CEM | HeLa | HMEC-1 |
|----------|--------|-------|-------|-----|------|--------|
| 2a       | ≥100   | 23 ± 9 | ≥100  | >100| >100 | >100   |
| 2b       | 3 ± 2  | 0.6 ± 0.1 | ≥100 | >100| >100 | >100   |
| 2c       | ≥100   | 21 ± 0.03 | ≥100 | 58 ± 7 | 88 ± 8 | >100 |
| 2d       | 36 ± 3 | ≥100  | ≥100 | nd  | nd   | 100    |
| 2e       | 27 ± 0.06 | 32 ± 4 | 85 ± 13.5 | nd  | nd   | nd     |
| 2f       | 22 ± 21 | ≥100  | ≥100 | nd  | nd   | nd     |
| 2g       | 77 ± 7 | ≥100  | ≥100 | nd  | nd   | nd     |
| 2h       | 9 ± 3  | 0.3 ± 0.2 | 29 ± 3 | >100| >100 | >100   |
| 2i       | 7 ± 3  | 1 ± 0.1 | ≥100 | >100| >100 | >100   |
| 4a       | 31 ± 6 | 3 ± 2  | 21 ± 7 | ≥100| 79 ± 36 | 66 ± 4 |
| 4b       | 31 ± 5 | 19 ± 3 | 23 ± 10 | 74 ± 37 | 25 ± 0 | 69 ± 8 |
| 5-FU     | 4 ± 1  | 14 ± 0.3 | 3 ± 0.3 | nd  | nd   | nd     |
| etoposide | 5 ± 2  | 1 ± 0.7 | 0.1 ± 0.04 | nd  | nd   | nd     |

*IC$_{50}$: the concentration that causes 50% growth inhibition, b nd: not determined, c 5-FU: 5-fluorouracil.
Table 1. IC\textsubscript{50} values (\textmu M) of tested compounds against HCT116, MCF-7, H\textsubscript{460}, CEM, HeLa HMEC-1 cells.

| Compound | HCT116 | MCF-7 | H\textsubscript{460} | CEM | HeLa | HMEC-1 |
|----------|--------|-------|--------------------|-----|------|--------|
| 2a       | ≥100   | ≥100  | ≥100               | >100| >100 | >100   |
| 2b       | 3 ± 2  | 0.6 ± 0.1 | ≥100          | >100| >100 | >100   |
| 2c       | ≥100   | 21 ± 0.03 | ≥100           | 58 ± 7| 88 ± 8| >100   |
| 2d       | 36 ± 3 | ≥100  | ≥100              |      |      |        |
| 2e       | 27 ± 0.06 | 32 ± 4 | 85 ± 13.5      |      |      |        |
| 2f       | 22 ± 21 | ≥100  | ≥100             |      |      |        |
| 2g       | 77 ± 7 | ≥100  | ≥100             |      |      |        |
| 2h       | 9 ± 3  | 0.3 ± 0.2 | 29 ± 3       | >100| >100 | >100   |
| 2i       | 7 ± 3  | 1 ± 0.1 | ≥100           | >100| ≥100 | >100   |
| 4a       | 31 ± 6 | 3 ± 2  | 21 ± 7         | ≥100| 79 ± 36| 66 ± 4 |
| 4b       | 31 ± 5 | 19 ± 3 | 23 ± 10       | 74 ± 37| 25 ± 0 | 69 ± 8 |
| 5-FU     | 4 ± 1  | 14 ± 0.3 | 3 ± 0.3      |      |      |        |

\textsuperscript{a} IC\textsubscript{50}; the concentration that causes 50\% growth inhibition, \textsuperscript{b} nd; not determined, \textsuperscript{c} 5-FU; 5-fluorouracil.

Figure 3. Concentration-response profiles for compounds 2b (a) and 2h (b) tested in vitro on human tumour cell lines HCT116, MCF-7 and H460.

Bis(coumarin-1,2,3-triazolyl)benzenes 2h and 2i were generally the most cytotoxic compounds, especially 1,3-bis(coumarin-triazolyl) derivative 2h with strong inhibitory activity against breast (MCF-7: IC\textsubscript{50} = 0.3 \textmu M) and colon carcinoma (HCT116: IC\textsubscript{50} = 9 \textmu M). Its 1,4-disubstituted structural isomer 2i displayed slightly reduced cytotoxicity with IC\textsubscript{50} = 1 and 7 \textmu M against MCF-7 and HCT116 cells, respectively.

Two coumarin-1,2,3-triazole-benzazole hybrids 4a and 4b were also evaluated and demonstrated almost the same moderate activity against all cell lines. Additionally, benzothiazole derivative 4a showed more pronounced selectivity than its benzimidazole congener 4b against MCF-7 cell lines, with IC\textsubscript{50} = 3 \textmu M.

Interestingly, MCF-7 cell line was especially sensitive towards almost all synthesised compounds with IC\textsubscript{50} = 0.3–32 \textmu M except for 2d, f and g, which were devoid of activity against this cancer cell line. The HMEC-1 cell line was almost completely insensitive to all tested compounds.

2.3. Antiviral Activities In Vitro

The antiviral activity of synthesised compounds (2a–c, 2h–i and 4a–b) was tested against Herpes simplex virus 1 and 2, vaccinia virus, adeno virus-2, human coronavirus, vesicular stomatitis virus, respiratory syncytial virus, reovirus-1, Sindbis virus, Coxsackie virus B4, Punta Toro virus, varicella-zoster virus, cytomegalovirus and yellow fever virus. None of the compounds showed any significant antiviral activity (data not shown).

2.4. Spectroscopic Characterisation

The structures of all compounds were determined by NMR analysis (based on inspecting H–H coupling constants and chemical shifts). Generally, \textsuperscript{1}H NMR spectra of all 1,2,3-triazolyl-coumarin derivatives showed characteristic protons at C5 of triazole at 8.95–9.66 ppm, and proton at C2 of coumarin moiety at approximately 6.5 ppm. \textsuperscript{1}H and \textsuperscript{13}C NMR and HRMS spectral data for compounds 2a–i and 4a–b are summarised in Table S1.
UV-Visible Absorption and Fluorescence Emission Spectra

Coumarin derivatives are widely used as fluorophores in fluorescent probes and fluorescent tags for biological molecules. Conventional coumarin dyes typically absorb at and are excited by UV light, with emission in the blue spectral region [35]. However, excitation at short wavelengths is not desirable for bioimaging applications because of possible autofluorescence and photo-induced damage of tissue. With an appropriate substitution in the 3- and/or 7-position of the coumarin ring, the derivatives obtained can emit strong fluorescence in the blue-green region (400–550 nm). For example, introduction of an 1,2,3-triazole ring at 3- or 7-position of coumarin has been shown to strongly affect their fluorescent properties [36,37]. Therefore, spectroscopic characterisation of newly synthesised coumarin derivatives 2a–g and 4a–b containing different substituents conjugated via 1,2,3-triazole linker, as well as bis(triazolyl-coumarin)benzenes 2h–i, was conducted. UV-Vis absorption and fluorescence emission spectra were measured in dimethyl sulfoxide (DMSO) at the compound concentration of 1.0 × 10⁻⁵ mol dm⁻³ and are presented in Figure 4.

Figure 4. UV-Vis absorption (a,c,e) and fluorescence emission spectra (b,d,f) of: 2a–g (a,b); 2h–2i (c,d) and 4a–b (e,f) in DMSO (c = 10 μM), λexc = λabs,max.

- **UV-Vis absorption spectra**

The coumarin oxygen atom has sp² hybridization and is a part of the π-system of the molecule, so the spectrum may show an n→π* electronic transition in addition to a number of π→π* transitions. Compound 2a, containing an unsubstituted phenyl ring exhibited spectra with the absorption maximum at 328 nm. Compounds 2a–g displayed absorption...
spectra of similar general shape as 2a, with the main absorption band in the range of 325–331 nm and generally lower molar absorption coefficient depending on substituents on the phenyl ring ($\varepsilon = 13,500–23,200$ M$^{-1}$ cm$^{-1}$) (Figure 4a). However, aminophenyl and N,N-dimethylaminophenyl substituted derivatives 2b and 2c show greatly enhanced absorption in the range 284–296 nm with high extinction coefficients ($\varepsilon > 39,000$ M$^{-1}$ cm$^{-1}$) accompanied by a shoulder peak at around 325 nm. Methoxyphenyl-substituted 2f showed slight bathochromic shift (4 to 6 nm) compared to compounds 2a–e and 2g. The observed absorption bands are assigned to the $\pi\rightarrow\pi^*$ electronic transitions characteristic for the whole coumarin ring system, while the expected n$\rightarrow\pi^*$ transition may be submerged under the stronger $\pi\rightarrow\pi^*$ transition.

1,4-Bis(triazolyl-coumarin)benzene 2i showed the most intense absorption bands at 278 and 326 nm ($\varepsilon = 53,700$ and 39,700 M$^{-1}$ cm$^{-1}$) in the series of studied compounds 2. 1,3-bis-disubstituted analogue 2h showed slightly different absorption spectra, exhibiting one noticeable maximum at 326 nm and a shoulder at 292 nm with considerably lower molar extinction coefficients ($\varepsilon = 14,400$ M$^{-1}$ cm$^{-1}$ and 12,200 M$^{-1}$ cm$^{-1}$) (Figure 4c).

Introduction of benzazole ring to coumarin-triazolyl hybrids 4a and 4b resulted in absorption spectra with two maxima in the range of 285–292 nm ($\varepsilon = 29,200–38,800$ M$^{-1}$ cm$^{-1}$) and a shoulder around 325 nm ($\varepsilon = 17,600–22,500$ M$^{-1}$ cm$^{-1}$) (Figure 4e).

Fluorescence emission spectra

Considering the fluorescence emission spectra, compounds 2a–g displayed single emission bands with variable emission maxima and intensity, depending on the substituents at 1,2,3-triazole, as shown in Figure 4b. Phenyl-unsubstituted derivative 2a displayed an emission band with a maxima at 406 nm, while substitution at phenyl ring in compounds 2b–g resulted in bathochromic shifts of emission maxima (5 to 111 nm), with the exception of bromo-substituted derivative 2e. As shown in Figure 4b, p-tolyl substituted derivative 2d showed the most pronounced fluorescence intensity at 445 nm, while 2c did not fluoresce at all in DMSO. Despite emitting at 517 nm and showing the largest Stokes shift of all compounds (187 nm), 2f displayed quite low fluorescence in comparison to other conjugates. It should be noted that all the derivatives 2 exhibit large Stokes shifts (64–187 nm) and therefore have the potential for application as molecular probes and light-emitting markers in chemistry and biology. Additionally, it can be noticed that introduction of strong electron-donating substituents on the phenyl ring results in lowering of quantum yields. As the electron-donating strength of substituents on the phenyl ring decreases in order $2c$ (NMe$_2$), $2b$ (NH$_2$), $2f$ (OMe), the respective quantum yields increase in the same order 0.004, 0.035, 0.058 reaching the highest value of 0.445 for weakly electron-donating methyl group in 2d. The respective molar absorption coefficients follow the same trend and increase with increasing electron-donating ability of the substituent ranging from 15,100 for 2d to 41,000 M$^{-1}$ cm$^{-1}$ for 2c.

Bis(coumarin-triazolyl)benzenes showed rather different emission spectra. 1,3-bis derivative 2h exhibited an emission maximum at the lowest wavelength of all compounds, emitting at 394 nm. However, 1,4-disubstitution on benzene ring resulted in a bathochromic shift, and the observed emission maximum of 2i was at 415 nm (Figure 4d).

Interestingly, triazolyl-coumarins with benzazole moiety 4a and 4b showed dual emission in DMSO, with maxima at 350 and 416 nm (4a), and 357 and 418 nm (4b) (Figure 3c). Organic fluorophores with dual emission properties are especially interesting for application in white light electroluminescence and luminescent bioimaging [38]. Dual emission most commonly occurs as a result of photoinduced structural rearrangement and charge re-distribution in fluorophore molecules, so further studies are underway to investigate this. The basic photophysical properties of 2a–i and 4a–b in DMSO are summarised in Table 2.
Table 2. Absorption and emission data of studied compounds in DMSO.

| Compound | 2a | 2b | 2c | 2d | 2e | 2f | 2g | 2h | 2i | 4a | 4b |
|----------|----|----|----|----|----|----|----|----|----|----|----|
| λ_{abs}/nm | 328 | 284 | 296 | 325 | 327 | 331 | 300 | 325 | 292 | 287 | 292 |
| \(\varepsilon\) × 10³/dm³ mol⁻¹ cm⁻¹ | 28.7 | 39.7 | 15.3 | 41.0 | 15.1 | 23.2 | 18.1 | 11.4 | 13.4 | 14.4 | 13.7 |
| λ_{emis}/nm | 406 | 412 | 418 | 455 | 401 | 517 | 411 | 394 | 415 | 416 | 350 |
| Rel. Fluo. Int. | 292.7 | 92.6 | 4.3 | 593.3 | 229.3 | 43.1 | 63.0 | 451.4 | 119.3 | 362.6 | 396.8 |
| Stokes shift/nm | 78 | 129 | 87 | 123 | 126 | 73 | 187 | 84 | 64 | 88 | 91 |
| \(\Phi\) | 0.212 | 0.035 | 0.004 | 0.445 | 0.136 | 0.058 | 0.021 | 0.127 | 0.029 | 0.018 | 0.025 |

Absorption and fluorescence spectra were recorded at compound concentration \(c = 1 \times 10^{-3} \text{M}\), \(\lambda_{exc} = \lambda_{abs,max}\), slit width = 5-5. Stock solutions of compounds were prepared in DMSO.

3. Materials and Methods

3.1. General Methods

All chemicals and solvents were purchased from commercial suppliers Acros (Antwerp, Belgium), Sigma Aldrich (St. Louis, MO, USA) or Fluka (Buchs, Switzerland) and used as received without further purification. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 300 (Bruker, Billerica, MA, USA) or Bruker Avance 600 (Bruker, Billerica, MA, USA) at 300, 600, and 150 and 75 MHz, respectively. All NMR spectra were measured in DMSO-d₆ solutions, while chemical shifts are reported in ppm (δ) relative to TMS as the internal standard. Individual resonances were assigned on the basis of their chemical shifts, signal intensities, multiplicity of resonances. Melting points were recorded on SMP10 Bibby apparatus (Barloworld Scientific, Staffordshire, UK). The electronic absorption spectra were recorded on a Varian Cary 50 spectrometer (Varian, Inc., Palo Alto, California, USA) using a quartz cuvette (1 cm). Mass spectra were recorded on Bruker Microflex MALDI/TOF mass spectrometer (Bruker, Billerica, MA, USA) using positive ionization. All compounds were routinely checked by TLC using Merck silica gel 60F-254 glass plates. The spectral data can be found in Supplementary Materials in Table S1 and Figures S1–S25.

3.2. Procedures for the Preparation of Compounds

3.2.1. 7-Azido-4-methyl-2H-chromen-2-one (1)

**Method A:** 7-Amino-4-methylcoumarin (300.0 mg, 1.71 mmol) was dissolved in anhydrous acetonitrile (10 mL) and cooled to 0°C in an ice bath. Then, t-BuONO (0.34 mL, 2.86 mmol) and TMSN₃ (0.28 mL, 2.11 mmol) were added dropwise and the reaction mixture was stirred at room temperature for 2 h. The solvent was evaporated under reduced pressure and crude orange/brown compound 1 (136.0 mg, 40%) was isolated.

**Method B:** To a solution of 7-amino-4-methylcoumarin (100.0 mg, 0.57 mmol) and p-toluenesulphonic acid monohydrate (977.4 mg, 5.14 mmol) in 5.0 mL of H₂O, NaNO₂ (354.4 mg, 5.14 mmol) was gradually added. After stirring of the reaction mixture for 1 h at room temperature, NaN₃ (59.4 mg, 0.91 mmol) was added and immediate emission of N₂ was observed. The resulting mixture was stirred overnight, filtered, washed with water and pure compound 1 (78.0 mg, 68%) as orange/brown powder was isolated; m.p. 163–172°C.

¹H NMR (600 MHz, DMSO-d₆): δ/ppm = 7.77 (d, 1H, J = 8.5 Hz), 7.14–7.10 (m, 2H), 6.32 (s, 1H), 2.40 (s, 3H). ¹³C NMR (75 MHz, DMSO-d₆): δ/ppm = 154.5, 153.4, 143.8, 128.5, 127.5, 117.2, 116.1, 113.7, 107.3, 18.6.

3.2.2. General Procedure for the Synthesis of Propargylated Benzothiazole (3a) and Benzimidazole (3b) Derivatives

To a solution of 2-mercaptobenzothiazole (600.0 mg, 3.59 mmol) or 2-mercaptobenzimidazole (600.0 mg, 4.0 mmol) in dry THF (5 mL) triethylamine (1.5 eq) was added and reaction
mixture was stirred for 15 min at room temperature. Afterwards, propargyl bromide (1.0 eq) was added and mixture was heated to reflux till its completion. After 4h the solvent was evaporated under reduced pressure and crude residue was purified by recrystallisation from ethanol (5 mL).

2-(Prop-2-ynylthio)benzo[d]thiazole (3a)

Brown crystals of compound 3a were isolated (240.0 mg, 33%); m.p. 95 °C.

\[ ^{1}H \text{NMR (300 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 8.05 \text{ (d, 1H, } J = 7.9 \text{ Hz), 7.89 \text{ (d, 1H, } J = 7.5 \text{ Hz), 7.48 (td, 1H, } J_1 = 7.7 \text{ Hz, } J_2 = 1.3 \text{ Hz), 7.39 (td, 1H, } J_1 = 7.6 \text{ Hz, } J_2 = 1.2 \text{ Hz), 4.25 (d, 2H, } J = 2.6 \text{ Hz), 3.31 (bs, 1H).} \]

\[ ^{13}C \text{NMR (75 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 165.5, 153.0, 135.3, 126.9, 125.1, 122.4, 121.8, 79.8, 75.2, 21.5. \]

2-(Prop-2-ynylthio)-1H-benzo[d]imidazole (3b)

White crystals of compound 3b were isolated (197.0 mg, 26%); m.p. 173 °C.

\[ ^{1}H \text{NMR (600 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 12.63 \text{ (s, 1H), 7.53 (d, 1H, } J = 7.4 \text{ Hz), 7.38 (d, 1H, } J = 7.3 \text{ Hz), 7.14–7.11 (m, 2H), 4.13 (s, 2H), 3.19 (s, 1H).} \]

\[ ^{13}C \text{NMR (75 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 153.6, 148.8, 122.0, 109.9, 80.5, 74.5, 20.2. \]

3.2.3. General Procedure for the Synthesis of Coumarin-Triazolyl-Aryl Conjugates 2a–g

7-Azido-4-methyl-2H-chromen-2-one 1 (30.0 mg, 0.15 mmol) and the corresponding aromatic alkyne (1 eq) were dissolved in t-BuOH/H$_2$O/CH$_2$Cl$_2$ = 1:2:1 (8.0 mL). Next, 1 M CuSO$_4$ × 5 H$_2$O (0.04 mL), Na-ascorbate (33.7 mg, 0.17 mmol) and TBTA (tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) (4.0 mg, 0.0075 mmol) were added to this solution. Reaction mixture was stirred for 48 h at room temperature. Progress of the reaction was monitored by TLC using dichloromethane and methanol as eluent. The reaction mixture was evaporated to dryness under reduced pressure and crude residue was purified by column chromatography on silica gel with dichloromethane/methanol (200:1) as eluent to afford 2a–g in 11%–59% yield.

4-Methyl-7-(4-phenyl-1H-1,2,3-triazol-1-yl)-2H-chromen-2-one (2a)

Compound 2a was prepared according to above procedure starting from azidocoumarin 1 and ethynylbenzene (1 eq). After stirring for 48 h and purification, compound 2a (28.0 mg, 25%) was isolated as yellow powder; m.p. 267–270 °C.

\[ ^{1}H \text{NMR (300 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 9.49 \text{ (s, 1H), 8.05 \text{ (s, 3H), 7.97 \text{ (d, 2H, } J = 7.1 \text{ Hz), 7.56–7.51 (m, 2H), 7.45–7.40 (m, 1H), 6.52 \text{ (s, 1H), 2.74 \text{ (s, 1H).} }^{13}C \text{NMR (75 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 159.9, 154.2, 153.2, 148.1, 139.0, 130.4, 129.6, 129.0, 127.8, 125.9, 120.3, 120.0, 115.9, 115.2, 107.8, 18.6. HRMS (MALDI TOF/TOF) m/z calcld for C$_{18}$H$_{14}$N$_3$O$_2$ [M + H]$^+$: 304.1081, found [M + H]$^+$: 304.1096. \]

7-[4-(4-Aminophenyl)-1H-1,2,3-triazol-1-yl]-4-methyl-2H-chromene-2-one (2b)

Compound 2b was synthesised as described from azidocoumarin 1 and 4-ethylaniline (1 eq). After stirring for 48 h and column chromatography, dark yellow powder of 2b was obtained (30.0 mg, 17%); m.p. 267–273 °C.

\[ ^{1}H \text{NMR (300 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 9.17 \text{ (s, 1H), 8.01 \text{ (s, 3H), 7.97 \text{ (d, 2H, } J = 7.1 \text{ Hz), 7.56–7.51 (m, 2H), 7.45–7.40 (m, 1H), 6.52 \text{ (s, 1H), 2.74 \text{ (s, 1H).} }^{13}C \text{NMR (75 MHz, DMSO-}d_6\text{): } \delta/\text{ppm} = 152.3, 154.2, 152.3, 148.1, 139.0, 130.4, 129.0, 127.8, 125.9, 120.3, 120.0, 115.9, 115.2, 107.8, 18.6. HRMS (MALDI TOF/TOF) m/z calcld for C$_{18}$H$_{15}$N$_4$O$_2$ [M + H]$^+$: 319.1190, found [M + H]$^+$: 319.1203. \]

7-[4-(4-(Dimethylamino)phenyl)-1H-1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (2c)

Compound 2c was synthesised according to described procedure, from azidocoumarin 1 and 4-ethyl-N,N-dimethylaniline (1 eq) after stirring for 48 h. After column chromatography compound 2c (15.7 mg, 15%) was obtained as pale yellow powder; m.p. 275–279 °C.
Molecules 2022, 27, 637

1H NMR (600 MHz, DMSO-d$_6$): δ/ppm = 9.25 (s, 1H), 8.02 (s, 3H), 7.76 (d, 2H, J = 8.5 Hz), 6.84 (d, 2H, J = 8.7 Hz), 6.49 (s, 1H), 2.97 (s, 6H), 1.23 (s, 3H). $^{13}$C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 167.3, 159.9, 153.3, 150.9, 148.8, 128.4, 127.7, 126.8, 125.9, 118.1, 118.0, 115.7, 115.0, 112.8, 107.6, 29.5, 18.6. HRMS (MALDI TOF/TOF) m/z calcd for C$_{20}$H$_{19}$N$_4$O$_2$ [M + H]$^+$: 347.1503, found [M + H]$^+$: 347.1496.

4-Methyl-7-[4-(p-tolyl)-1H,1,2,3-triazol-1-yl]-2H-chromen-2-one (2d)

Compound 2d was prepared following above procedure from azidocoumarin 1 and 1-ethynyl-4-methylbenzene (1 eq). The stirring of reaction mixture for 48 h and purification by column chromatography yielded 2d (50.3 mg, 41%) as pale yellow powder; m.p. 269–272 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.42 (s, 1H), 8.03 (s, 3H), 7.84 (d, 2H, J = 8.1 Hz), 7.33 (d, 2H, J = 7.9 Hz), 6.50 (s, 1H), 2.36 (s, 3H), 1.23 (s, 3H). $^{13}$C NMR (150 MHz, DMSO-d$_6$): δ/ppm = 159.4, 153.7, 152.7, 147.7, 138.5, 137.9, 129.6 (2C), 127.3, 127.1, 125.3 (2C), 119.4, 115.3, 114.6, 112.7, 107.3, 20.8, 18.6. HRMS (MALDI TOF/TOF) m/z calcd for C$_{19}$H$_{16}$N$_3$O$_2$ [M + H]$^+$: 318.1237, found [M + H]$^+$: 318.1239.

7-[4-(4-Bromophenyl)-1H,1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (2e)

Compound 2e was obtained according to above procedure starting from azidocoumarin 1 and 1-bromo-4-ethynylbenzene (1 eq). The reaction mixture was stirred for 48 h and purified to yield compound 2e (83.0 mg, 59%) as yellow powder; m.p. 280–285 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.63 (s, 1H), 8.03 (s, 3H), 7.91 (d, 2H, J = 8.5 Hz), 7.74 (d, 2H, J = 8.5 Hz), 6.51 (s, 1H), 2.73 (s, 3H). $^{13}$C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 159.9, 154.1, 153.2, 147.1, 138.9, 138.3, 129.7, 127.8, 122.0, 120.7, 120.1, 115.9, 115.2, 107.9, 18.6. HRMS (MALDI TOF/TOF) m/z calcd for C$_{18}$H$_{13}$BrN$_3$O$_2$ [M + H]$^+$: 382.0186, found [M + H]$^+$: 382.0194.

7-[4-(4-Methoxyphenyl)-1H,1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (2f)

Compound 2f was synthesised as described from azidocoumarin 1 and 1-ethynyl-4-methoxybenzene (1 eq). After stirring for 48 h and column chromatography pale yellow powder of compound 2f was obtained (62.4 mg, 51%); m.p. 266–270 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.66 (s, 1H), 8.03 (s, 3H), 7.88 (d, 2H, J = 8.8 Hz), 7.09 (d, 2H, J = 8.8 Hz), 6.50 (s, 1H), 3.82 (s, 3H) 2.73 (s, 3H). $^{13}$C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 159.9, 159.9, 154.2, 153.2, 148.1, 138.9, 138.3, 129.7, 127.8, 122.0, 120.7, 120.1, 115.9, 115.2, 107.9, 18.6. HRMS (MALDI TOF/TOF) m/z calcd for C$_{19}$H$_{16}$N$_3$O$_3$ [M + H]$^+$: 334.1186, found [M + H]$^+$: 334.1200.

4-[1-(4-Methyl-2-oxo-2H-chromen-7-yl)-1H,1,2,3-triazol-4-yl]benzaldehyde (2g)

Compound 2g was prepared as described from azidocoumarin 1 and 4-ethynylbenzaldehyde (1 eq). The mixture was stirred for 48 h and chromatographed to yield compound 2g (13.0 mg, 11%) as yellow powder; m.p. 282–287 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 10.12 (s, 1H), 9.66 (s, 1H), 8.48 (s, 1H), 8.28 (d, 1H, J = 7.7 Hz), 8.05 (s, 3H), 7.97 (d, 1H, J = 7.6 Hz), 7.81–7.76 (m, 1H), 6.51 (s, 1H), 2.73 (s, 3H). $^{13}$C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 193.0, 168.5, 159.4, 154.6, 153.7, 152.7, 143.2, 138.5, 131.1, 131.0, 130.1, 129.8, 127.4, 125.6, 120.6, 115.4, 114.8, 107.4, 18.1. HRMS (MALDI TOF/TOF) m/z calcd for C$_{19}$H$_{14}$N$_3$O$_3$ [M + H]$^+$: 332.1030, found [M + H]$^+$: 332.1024.

7-[4-[(Benzo[d]thiazol-2-yl)thio]methyl]-1H,1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (4a)

Compound 4a was synthesised according to above procedure using azidocoumarin 1 and propargylated benzothiazole derivative 3a (1 eq). After stirring of reaction mixture at 60 °C for 24 h and purification of raw material, crude dark yellow compound 4a (50.0 mg, 55%) was isolated; m.p. 186–192 °C.
1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.00 (s, 1H), 8.03–7.92 (m, 5H), 7.49 (t, 1H, J = 7.6 Hz), 7.40–7.35 (m, 1H), 6.46 (s, 1H), 4.82 (s, 2H), 2.47 (s, 3H). 13C NMR (150 MHz, DMSO-d$_6$): δ/ppm = 156.5, 159.4, 153.6, 152.7, 152.5, 144.2, 138.3, 134.7, 127.2, 126.4, 124.6, 122.3, 121.8, 121.3, 119.5, 115.5, 114.7, 107.4, 27.2, 18.1. HRMS (MALDI TOF/TOF) m/z calc for C$_{29}$H$_{14}$N$_{4}$O$_2$S$_2$Na [M + Na]$^+$: 429.0450, found [M + Na]$^+$: 429.0471.

7-[(1H-Benzol[d]imidazol-2-yl)thio][1H-1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (4b)

Compound 4b was prepared as described starting with azidocoumarin 1 and propargylated benzimidazole derivative 3b (1 eq). After stirring at 60 °C for 24 h and column chromatography yellow powder of compound 4b (113.0 mg, 68%) was obtained; m.p. 237–244 °C.

1H NMR (600 MHz, DMSO-d$_6$): δ/ppm = 12.91 (s, 1H), 8.95 (s, 1H), 7.95–7.89 (m, 3H), 7.55 (bs, 1H), 7.44 (bs, 1H), 7.15–7.13 (m, 2H), 6.47 (s, 1H), 4.78 (s, 2H) 2.46 (s, 3H). 13C NMR (150 MHz, DMSO-d$_6$): δ/ppm = 159.4, 153.4, 152.7, 152.6, 147.6, 138.5, 137.8, 136.5, 127.3, 127.2, 120.1, 119.4, 116.1, 115.5, 115.1, 114.7, 108.3, 107.5, 31.2, 25.6, 18.0. HRMS (MALDI TOF/TOF) m/z calc for C$_{30}$H$_{15}$N$_{5}$O$_2$S$_2$Na [M + Na]$^+$: 412.0839, found [M + Na]$^+$: 412.0837.

3.2.4. General Procedure for the Preparation of Bis(coumarin-1,2,3-triazolyl)benzenes 2h-i

7-azido-4-methyl-2H-chromen-2-one (1 eq) and 1,3-diethynylbenzene (0.5 eq). After stirring for 72 h at r.t. and column chromatography yellow powder of compound 2h was prepared as described starting with azidocoumarin 1 and propargylated benzimidazole derivative 3b (1 eq). After stirring at 60 °C for 24 h and column chromatography yellow powder of compound 4b (113.0 mg, 68%) was obtained; m.p. 237–244 °C.

7,7'-[4-[(1H-Benzol[d]imidazol-2-yl)thio][1H-1,2,3-triazol-1-yl]-4-methyl-2H-chromen-2-one (2h)

Compound 2h was synthesised following described method from azidocoumarin 1 (1.0 eq) and 1,3-diethynylbenzene (0.5 eq). After stirring for 48 h at r.t. and purification, compound 2h as yellow powder was isolated (20.4 mg, 51%); m.p. 247–253 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.56 (s, 2H), 8.03–8.01 (m, 6H), 7.52–7.51 (m, 3H), 6.49 (s, 2H), 1.33 (s, 6H). 13C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 159.9, 154.1, 153.2, 147.1, 138.9, 132.0, 130.9, 130.1, 128.9, 127.9, 126.2, 124.6, 123.0, 120.1, 115.9, 115.2, 115.1, 18.6. HRMS (MALDI TOF/TOF) m/z calc for C$_{30}$H$_{20}$N$_{6}$O$_4$ [M]$^+$: 528.1546, found [M]$^+$: 528.1550.

7,7'-[4-[(1,4-Phenylene)bis(1H-1,2,3-triazol-1-yl)]bis(4-methyl-2H-chromen-2-one) (2i)

Compound 2i was prepared from azidocoumarin 1 (1.0 eq) and 1,4-diethynylbenzene (0.5 eq). After stirring for 72 h at r.t. and column chromatography, compound 2i (13.7 mg, 35%) was isolated as yellow powder; m.p. 255–261 °C.

1H NMR (300 MHz, DMSO-d$_6$): δ/ppm = 9.54 (s, 2H), 8.03 (s, 4H), 7.98–7.62 (m, 6H), 6.50 (s, 2H), 1.23 (s, 6H). 13C NMR (75 MHz, DMSO-d$_6$): δ/ppm = 159.9, 154.1, 153.2, 138.9, 133.0, 130.8, 127.9, 126.0, 122.1, 120.9, 120.1, 115.9, 115.2, 107.9, 18.6. HRMS (MALDI TOF/TOF) m/z calc for C$_{30}$H$_{20}$N$_{6}$O$_4$ [M]$^+$: 528.1546, found [M]$^+$: 528.1550.

3.3. Spectroscopic Characterisation

Spectrophotometric absorbance and fluorescence measurements were carried out using 1.0 × 10$^{-5}$ M solutions of compounds. Measurements were conducted by diluting stock solutions of 2 and 4 in DMSO due to the good solubility of all compounds in this solvent.

UV-Vis absorption spectra were recorded, against the solvent, at (25 ± 0.1) °C, using a Varian Cary spectrophotometer in double-beam mode. Quartz cells of 1 cm path length were used throughout. The wavelength range covered was from 200 to 500 nm. Fluores-
cence measurements were carried out on a Varian Cary Eclipse fluorescence spectrophotometer at 25 °C using 1 cm path quartz cells. Excitation wavelengths were determined from absorbance maxima. Emission spectra were recorded from 200 to 700 nm. Relative fluorescence quantum yields were determined according to Miller using Equation (1):

\[ \Phi_x = \Phi_s \times \frac{A_sD_s n_s^2}{A_xD_x n_x^2} \]  

where \( \Phi \) is the emission quantum yield, \( A \) is the absorbance at the excitation wavelength, \( D \) is the area under the corrected emission curve and \( n \) is the refractive index of the solvents used. The subscripts \( s \) and \( x \) refer to the standard and to the unknown, respectively. The standard employed was quinine sulphate with a published fluorescence quantum yield of 0.54 [39].

3.4. Antiproliferative Activity In Vitro

The experiments were carried out on several human cell lines, as follows: HCT116 (colon carcinoma), H 460 (lung carcinoma) and MCF-7 (breast carcinoma), HeLa (cervical carcinoma), human T-lymphocyte cells (CEM) and HMEC-1 (dermal microvascular endothelial cell) according to the previously published experimental procedure [40,41]. Briefly, the cells were grown in DMEM medium with the addition of 10% foetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin and 100 \( \mu \)g/mL streptomycin, and cultured as monolayers at 37 °C in a humidified atmosphere with 5% CO\(_2\). HCT116, H 460 and MCF-7 cells were seeded at 2 \( \times \) 10\(^3\) cells/well in a standard 96-well microtiter plates and left to attach for 24 h. Next day, test compound was added in five serial 10-fold dilutions. The cell growth rate was evaluated after 72 h of incubation, using MTT assay. Obtained results were expressed as IC\(_{50}\) value which stands for the concentration of the compound necessary for 50% of growth inhibition. The IC\(_{50}\) values were calculated from concentration-response curve using linear regression analysis by fitting the test concentrations that give percentage of growth (PG) values above and below the reference value (i.e., 50%). However, if for a given cell line all of the tested concentrations produce PGs exceeding the respective reference level of effect (e.g., PG value of 50), then the highest tested concentration is assigned as the default value, which is preceded by a “>” sign. Each test was performed in quadruplicate in at least two individual experiments.

HeLa and HMEC-1 cells were seeded in 48-well plates at 10,000 cells/well. After 24 h, different concentrations of the compounds were added. After 3 days of incubation, the cells were trypsinized and counted in a Coulter counter. Suspension cells (human T-cell leukaemia Cem cells) were seeded in 96-well plates at 60,000 cells/well in the presence of different concentrations of compounds, allowed to proliferate for 96 h, and counted in a Coulter counter. The 50% inhibitory concentration (IC\(_{50}\)) was defined as the compound concentration required reducing cell proliferation by 50%.

4. Conclusions

In this work we present the synthesis of coumarin-triazole conjugates using the copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition. The synthesised compounds were characterised by \(^1\)H-NMR, \(^{13}\)C-NMR and HRMS. The synthesised compounds were tested against several human cancer cell lines (HCT116, MCF-7, H 460, CEM and HeLa) and non-tumour HMEC-1 cell line. The antiproliferative assay demonstrated moderate to pronounced activity of the compounds against some cancer cells, particularly against breast adenocarcinoma (MCF-7). Amongst coumarin-triazole-aryl hybrids, compound 2b with an amino substituent at the phenyl moiety showed the most pronounced activity towards MCF-7 cancer cells in submicromolar range (IC\(_{50}\) = 0.6 \( \mu \)M) and enhanced activity against HCT116 cells with IC\(_{50}\) = 3 \( \mu \)M. 1,3-Bis(coumarin-1,2,3-trazolyl)benzene 2h strongly inhibited growth of MCF-7 cells (IC\(_{50}\) = 0.3 \( \mu \)M). Its 1,4 structural congener showed somewhat reduced antiproliferative activity with IC\(_{50}\) = 1 \( \mu \)M against the same cancer cell line. The two coumarin-triazole-benzazole derivatives 4a and 4b showed very similar moderate activity against all of the cancer cell lines, whereas the presence of a benzothiazole or benz-
imidazole moiety had no influence on antiproliferative activity for 4a or 4b, respectively. Generally, the MCF-7 cell line showed the most evident sensitivity towards most of the tested compounds, while non-tumour human HMEC-1 cell line remained almost completely unaffected. Thus, further appropriate structural modification of the most effective molecular hybrids is prerequisite to deliver more potent new compounds with broad and improved biological properties.

The absorption and emission spectra of the synthesised compounds revealed some interesting optical properties. These include large Stokes shifts of the coumarin-triazole-aryl hybrids 2a–2g (78–187 nm) and the dual emission peaks of the benzazole derivatives 4a and 4b. These spectroscopic properties suggest that the molecules may also be suitable for use as molecular probes or in bioimaging. Further detailed photophysical studies of the synthesised compounds are underway.

Supplementary Materials: The following supporting information can be downloaded online.
Table S1: 1H and 13C NMR and HRMS spectral data and melting points for 1,2,3-triazolyl-coumarin derivatives 2a–i and 4a–b, Figures S1–S14: 1H and 13C NMR spectra of 1, 2a–i, 3a–b, 4a–b, Figures S15–S25: HRMS spectra of compounds 2a–i and 4a–b.

Author Contributions: Conceptualisation, S.K.; methodology, K.P., E.H., S.L., L.U. and M.K.; writing—original draft preparation, K.P., I.M.S., S.K. and M.K.; writing—review and editing, S.K. and I.M.S.; funding acquisition, I.M.S. All authors have read and agreed to the published version of the manuscript.

Funding: These materials are based on work supported by the University of Zagreb, under research grant number 121054 (2020), ‘Integrated analytical chemical systems: development and application of chemical sensors and biosensors’, grant number 121083 (2021), ‘Integrated analytical chemical systems: development and application of wearable sensors’ and the Croatian Science Foundation under grant number IP-2014-09-3386 entitled ‘Design and synthesis of novel nitrogen-containing heterocyclic fluorophores and fluorescent nanomaterials for pH and metal-ion sensing’.

Data Availability Statement: The data presented in this study are available in this article and the Supplementary Materials.

Acknowledgments: We gratefully acknowledge the University of Zagreb (grant numbers 121054 and 121083) and Croatian Science Foundation (grant number IP-2014-09-3386) for the financial support. The authors would also like to acknowledge Matthew Steinberg, PhD for English language and style proofreading and correction.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are available from the authors.

References
1. Zhang, L.; Xu, Z. Coumarin-containing hybrids and their anticancer activities. Eur. J. Med. Chem. 2019, 181, 111587. [CrossRef]
2. Thakur, A.; Singla, R.; Jaitak, V. Coumarins as anticancer agents: A review on synthetic strategies, mechanism of action and SAR studies. Eur. J. Med. Chem. 2015, 101, 476–495. [CrossRef] [PubMed]
3. Kostova, I.; Bhatia, S.; Grigorov, P.; Balkansky, S.; Parmar, V.S.; Prasad, A.K.; Saso, L. Coumarins as Antioxidants. Curr. Med. Chem. 2011, 18, 3929–3951. [CrossRef] [PubMed]
4. Hassan, M.Z.; Osman, H.; Ali, M.A.; Ahsan, M.J. Therapeutic potential of coumarins as antiviral agents. Eur. J. Med. Chem. 2016, 123, 236–255. [CrossRef]
5. Hu, Y.Q.; Xu, Z.; Zhang, S.; Wu, X.; Ding, J.W.; Lv, Z.S.; Feng, L.S. Recent developments of coumarin-containing derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017, 136, 122–130. [CrossRef]
6. Stefanachi, A.; Leonetti, F.; Pisani, L.; Catto, M.; Carotti, A. Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds. Molecules 2018, 23, 250. [CrossRef]
7. Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Simple coumarins and analogues in medicinal chemistry: Occurrence, synthesis and biological activity. Curr. Med. Chem. 2005, 12, 887–916. [CrossRef]
8. Anand, A.; Naik, R.J.; Revankar, H.M.; Kulkarni, M.V.; Dixit, S.R.; Joshi, S.D. A click chemistry approach for the synthesis of mono and bis aryloxy linked coumarinyl triazoles as anti-tubercular agents. Eur. J. Med. Chem. 2015, 105, 194–207. [CrossRef]
9. Ren, Q.C.; Gao, C.; Xu, Z.; Feng, L.S.; Liu, M.L.; Wu, X.; Zhao, F. Bis-coumarin Derivatives and their Biological Activities. Curr. Top. Med. Chem. 2018, 18, 101–113. [CrossRef] [PubMed]
10. Tasior, M.; Kim, D.; Singha, S.; Krzeszewski, M.; Ahn, K.H.; Gryko, D.T. II-Expanded coumarins: Synthesis, optical properties and applications. J. Mater. Chem. C 2015, 3, 1421–1446. [CrossRef]

11. Carbone, A.; Montalbano, A.; Sano, V.; Musante, I.; Galietta, L.J.V.; Barraja, P. Furocoumarins as multi-target agents in the treatment of cystic fibrosis. Eur. J. Med. Chem. 2019, 180, 283–290. [CrossRef]

12. Estévez-Braun, A.; González, A.G. Coumarins. Nat. Prod. Rep. 1997, 14, 465–475. [CrossRef]

13. Singh, H.; Singh, J.V.; Bhagat, K.; Gulati, H.K.; Sanduja, M.; Kumar, N.; Kinarivala, N.; Sharma, S. Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids. Bioorg. Med. Chem. 2019, 27, 3477–3510. [CrossRef]

14. Tornoe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: 1,2,3-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057–3064. [CrossRef]

15. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click chemistry: Diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 2001, 40, 2004–2021. [CrossRef]

16. Meldal, M.; Tornoe, C.W. Cu-Catalyzed Azide–Alkyne Cycloaddition. Chem. Rev. 2008, 108, 2952–3015. [CrossRef] [PubMed]

17. Bozorov, K.; Zhao, J.Y.; Aisa, H.A. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. Bioorg. Med. Chem. 2019, 27, 3511–3531. [CrossRef]

18. Zhang, W.J.; Li, Z.; Zhou, M.; Wu, F.; Hou, X.Y.; Luo, H.; Liu, H.; Han, X.; Yan, G.Y.; Ding, Z.Y.; et al. Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. Bioorg. Med. Chem. Lett. 2014, 24, 799–807. [CrossRef]

19. Kraljević, T.G.; Harej, A.; Sedić, M.; Kraljević-Pavelić, S.; Stepanić, V.; Drenjančević, D.; Talapko, J.; Raić-Malić, S. Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids. Eur. J. Med. Chem. 2016, 124, 794–808. [CrossRef]

20. Stefani, H.A.; Gueogjan, K.; Manarin, F.; Farsky, S.H.P.; Zukerman-Schpector, J.; Caracelli, I.; Rodrigues, S.R.P.; Muscara, M.N.; Teixeira, S.A.; Santin, J.R.; et al. Synthesis, biological evaluation and molecular docking studies of 3-(triazolyl)coumarin derivatives: Effect on inducible nitric oxide synthase. Eur. J. Med. Chem. 2012, 58, 117–127. [CrossRef] [PubMed]

21. Soto-Ortega, D.D.; Murphy, B.P.; Gonzalez-Velasquez, F.J.; Wilson, K.A.; Xie, F.; Wang, Q.A.; Moss, M.A. Inhibition of amyloid-beta aggregation by coumarin analogs can be manipulated by functionalization of the aromatic center. Bioorg. Med. Chem. 2011, 19, 2596–2602. [CrossRef]

22. Naik, R.J.; Kulkarni, M.V.; Pai, K.S.R.; Nayak, P.G. Click Chemistry Approach for Bis-Chromenyl Triazole Hybrids and Their Antitubercular Activity. Chem. Biol. Drug Des. 2012, 80, 516–523. [CrossRef] [PubMed]

23. Mir, F.; Shafi, S.; Zaman, M.S.; Kalia, N.P.; Rajput, V.; Mulakayala, C.; Mulakayala, N.; Khan, I.A.; Alam, M.S. Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents. Eur. J. Med. Chem. 2014, 76, 274–283. [CrossRef] [PubMed]

24. Osmaniye, D.; Levent, S.; Karaduman, A.B.; Ilgin, S.; Ozkay, Y.; Kaplançikli, Z.A. Synthesis of New Benzothiazole Acylhydrazones as Anticancer Agents. Molecules 2018, 23, 1054. [CrossRef] [PubMed]

25. Youssif, B.G.M.; Mohamed, Y.A.M.; Salim, M.T.A.; Inagaki, F.; Mukai, C.; Abdu-Allah, H.H.M. Synthesis of some benzimidazole derivatives endowed with 1,2,3-triazole as potential inhibitors of hepatitis C virus. Acta Pharm. 2016, 66, 219–231. [CrossRef]

26. Paramashivappa, R.; Kumar, P.P.; Rao, P.V.S.; Rao, A.S. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 657–660. [CrossRef]

27. Pereira, A.; Martins, S.; Caldeira, A. Coumarins as Fluorescent Labels of Biomolecules. In Phytochemicals in Human Health; Rao, V., Mans, D., Rao, L., Eds.; IntechOpen: London, UK, 2019; pp. 1–20.

28. Struthers, H.; Mindt, T.L.; Schibli, R. Metal chelating systems synthesized using the copper(I) catalyzed azide-alkyne cycloaddition. Dalton Trans. 2010, 39, 675–696. [CrossRef]

29. Watkinskon, M. Click Triazoles as Chemosensors. Top. Heterocycl. Chem. 2012, 28, 109–136.

30. Hua, Y.R.; Flood, A.H. Click chemistry generates privileged CH hydrogen-bonding triazoles: The latest addition to anion supramolecular chemistry. Chem. Soc. Rev. 2010, 39, 1262–1271. [CrossRef]

31. Jeon, M.K.; Kang, M.K.; Park, K.H. 7-Triazolylcoumarin-based fluorescent tag system for stepwise, comparative assessment of small molecule microarrays. Tetrahedron 2012, 68, 6038–6053. [CrossRef]

32. Barral, K.; Moorhouse, A.D.; Moses, J.E. Efficient conversion of aromatic amines into azides: A one-pot synthesis of triazole linkages. Org. Lett. 2007, 9, 1809–1811. [CrossRef]

33. Kutonova, K.V.; Trusova, M.E.; Postnikov, P.S.; Filimonov, V.D.; Parello, J. A Simple and Effective Synthesis of Aryl Azides via Arenediazonium Tosylates. Synthesis 2013, 45, 2706–2710.

34. Chan, T.R.; Hilgraf, R.; Sharpless, K.B.; Fokin, V.V. Polytriazoles as copper(I)-stabilizing ligands in catalysis. Org. Lett. 2004, 6, 2853–2855. [CrossRef]

35. Liu, X.G.; Cole, J.M.; Waddell, P.G.; Lin, T.C.; Radia, J.; Zeidler, A. Molecular Origins of Optoelectronic Properties in Coumarin Dyes: Toward Designer Solar Cell and Laser Applications. J. Phys. Chem. A 2012, 116, 727–737. [CrossRef] [PubMed]

36. Zhou, Z.; Fahrm, C.J. A fluorogenic probe for the copper(I)-catalyzed azide-alkyne ligation reaction: Modulation of the fluorescence emission via $3(n\pi^*\pi^{-1}(n\pi^*)$ inversion. J. Am. Chem. Soc. 2004, 126, 8862–8863. [CrossRef]
37. Key, J.A.; Koh, S.; Timerghazin, Q.K.; Brown, A.; Cairo, C.W. Photophysical characterization of triazole-substituted coumarin fluorophores. *Dyes Pigments* **2009**, *82*, 196–203. [CrossRef]

38. Xie, L.J.; Chen, Y.H.; Wu, W.T.; Guo, H.M.; Zhao, J.Z.; Yu, X.R. Fluorescent coumarin derivatives with large stokes shift, dual emission and solid state luminescent properties: An experimental and theoretical study. *Dyes Pigments* **2012**, *92*, 1361–1369. [CrossRef]

39. Melhuish, W.H. Quantum efficiencies of fluorescence of organic substances-effect of solvent and concentration of fluorescent solute. *J. Phys. Chem.* **1961**, *65*, 229–235. [CrossRef]

40. Lončar, B.; Perin, N.; Mioč, M.; Boček, I.; Grgić, L.; Kralj, M.; Tomić, S.; Stojković, M.R.; Hranjec, M. Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study. *Eur. J. Med. Chem.* **2021**, *217*, 113342. [CrossRef] [PubMed]

41. Perin, N.; Alić, J.; Liekens, S.; Van Aerschot, A.; Vervaeke, P.; Gadakh, B.; Hranjec, M. Different positions of amide side chains on the benzimidazo 1,2-a quinoline skeleton strongly influence biological activity. *New J. Chem.* **2018**, *42*, 7096–7104. [CrossRef]